Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostaserene
- Development stage
- Unknown
- Lead developer
- Therabel Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Prostaserene is a botanical extract medication developed and marketed by Therabel Group for the symptomatic treatment of urinary disorders associated with benign prostatic hyperplasia (BPH). The active ingredient is a lipophilic extract of *Serenoa repens* (saw palmetto) fruit, typically standardized to 320 mg per soft capsule and obtained through supercritical carbon dioxide extraction. Its mechanism of action is multi-targeted, exhibiting anti-inflammatory, anti-edematous, and anti-androgenic properties. Specifically, it inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reduces the activity of 5-alpha reductase, and modulates androgen and estrogen receptor activity within the prostate. Unlike synthetic BPH treatments such as 5-alpha reductase inhibitors or alpha-blockers, Prostaserene does not significantly alter prostate-specific antigen (PSA) levels, allowing for continued prostate cancer screening. It is administered orally as a once-daily dose for adult males.
- Brand names
- Prostaserene
- Other names
- Serenoa repens extractSaw palmetto extractLiposterolic extract of Serenoa repens
02
Targets
SRD5A (Steroid 5-alpha-reductase)AR (Adrenergic receptors)ALOX5 (Arachidonate 5-lipoxygenase)COXER (Estrogen receptor)
Beyond the preview
Go deeper on Prostaserene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prostaserene.